PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)

Inclusion Criteria:

1. Patient is eighteen years of age, or older (≥18) at time of consent.
2. Patient must meet the criteria for RA as defined by the 2010ACR/EULAR classificationat Visit 1 and documented by enrolling PI.
3. Patient has active RA, with moderate or high disease activity as confirmed by a CDAIscore of >10 at Visit 1.
4. Patients must have a history of failure, contraindication, or intolerance to at leastone csDMARD therapy.
5. Patient must be b/tsDMARD-naïve or TNFi-exposed prior to baseline visit only.
6. Patient must be initiating one of the following listed therapies (includingbiosimilars).
7. JAK inhibitor therapy (only tofacitinib or upadacitinib)
8. T-cell inhibitor therapy (abatacept)
9. IL-6 inhibitor therapy (only tocilizumab)
10. Concomitant treatments are permitted per standard of care and are not limited to thefollowing: a.csDMARD i.Methotrexate ii.Sulfasalazine iii.Leflunomide iv.Hydroxychloroquineb.Non-steroidal anti-inflammatory drugs c.Corticosteroids
11. Patient may participate in another observational study.
12. Patient is willing and able to complete the informed consent process and comply withall study procedures and visit schedule.

Exclusion Criteria:

1. Patient has previously participated in a Scipher Medicine study (NETWORK-004, AIMs inRA, DRIVE, or INFORM).
2. Patients who have been treated with an altMOA (non-TNFi therapy) therapy for RA priorto baseline (Visit 1).
3. Women who are known to be pregnant or breast-feeding or plan to get pregnant duringthe study duration.
4. Concurrent treatment with an investigational product or use of an investigationalproduct within 28 days of Visit 1.
5. The use of RA therapies outside of an FDA approved indication.
6. Patient is currently receiving systemic antimicrobial treatment for viral, bacterial,fungal, or parasitic infection at the time of baseline visit (Visit 1).
7. Any known active, chronic, or recurrent invasive infection (e.g., listeriosis andhistoplasmosis) and viral infection that, based on the Investigator's clinicalassessment, makes the patient an unsuitable candidate for the study. This includeshepatitis B virus (HBV) or hepatitis C virus (HCV), recurrent or disseminated (even asingle episode) herpes zoster, disseminated (even a single episode) herpes simplex, orhuman immunodeficiency virus (HIV).
8. Patient with any known active malignancy except non-melanoma skin cancer, localizedprostate cancer treated with curative intent with no evidence of progression, low-riskor very low-risk (per standard guidelines) localized prostate cancer undersurveillance/watchful waiting (without intent to treat),or carcinoma in situ of anytype.